AnteoTech Ltd and its controlled entities
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	AnteoTech Ltd
ABN:	75 070 028 625
Reporting period:	For the year ended 30 June 2026
Previous period:	For the year ended 30 June 2025

---

2. Unaudited results for announcement to the market

		%		$
Revenues from ordinary activities	down	52%	to	467,589
Interest and other income from ordinary activities	up	7%	to	2,661,555
Total revenue and other income from ordinary activities	down	10%	to	3,129,144
Loss from ordinary activities after tax attributable to the owners of AnteoTech Ltd	down	27%	to	(4,928,074)
Loss for the year attributable to the owners of AnteoTech Ltd	down	27%	to	(4,928,074)

The following unaudited information of AnteoTech Ltd for the year ended 30 June 2026 is attached:
- Consolidated Statement of Profit or Loss and Other Comprehensive Income
- Consolidated Statement of Financial Position
- Consolidated Statement of Changes in Equity
- Consolidated Statement of Cash Flows
- Notes to the Consolidated Financial Statements

Dividends
There were no dividends paid, recommended or declared during the current financial period.

Comments
The loss for the Group after providing for income tax amounted to $4,928,074 (30 June 2025: $6,759,135).

For the year ended 30 June 2026 the Group generated revenues from ordinary activities of $467,589 (2025: $968,878). Revenues comprised of both product sales and contract services in Life Sciences as well as the revenues from Advanced Battery Technologies.

The Company continued to receive recurring Life Sciences revenue under its five-year take-or-pay supply agreement with the Serum Institute of India (SII). The Company shipped $134,138 of AnteoBind™ to SII in July 2026. As the shipment was delivered post June 2026, this will be recorded as income in the following financial year.

Revenues and other income from ordinary activities for the year totalled $3,129,144 (2025: $3,458,728) and included the Research and Development tax concession claim for Financial Year 2026 of $2,588,632 (2025: $2,385,553).

Total expenses, excluding non-cash items such as depreciation and amortisation, and share-based payments were $6,410,307, a decrease of $2,040,807 year-on-year. The reduced expenses were primarily from lower salary and wages costs, professional services, Director fees, and research expenses. This aligns with the ASX announcement titled "Strategic Review Outcomes", released on 10 June 2025.

During the year, the Company significantly strengthened its balance sheet through the exercise of all its listed ADOO options (exercise price 3.5 cents (A$0.035)), which raised $10,032,004 (before costs) following the Company entering into an underwriting agreement with MST Financial Services Pty Ltd.

Cash on hand at the end of the period was $5,700,745 (2025: $2,340,306), plus the Company holds a $5,500,000 6-month Term Deposit maturing on 18 December 2026.

The Company received additional funding in January and February 2026 through a $3,808,350 Share Placement. The shares issued under the Placement were priced at 1.55 cents per share with an attaching option.

In October 2024, AnteoTech entered into a funding agreement with The Australian Renewable Energy Agency (ARENA) of up to $4,000,000. The date for satisfying the first milestone for the funding agreement has been extended until November 2026.

During the financial year, the Company withdrew from its funding agreement with the Queensland Critical Minerals and Battery Technology Fund.

---

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	0.36	0.12

---

4. Control gained over entities

Not applicable.

---

5. Loss of control over entities

Not applicable.

---

6. Dividends

Current period
There were no dividends paid, recommended or declared during the current financial period.

Previous period
There were no dividends paid, recommended or declared during the previous financial period.

---

7. Dividend reinvestment plans

Not applicable.

---

8. Details of associates and joint venture entities

Not applicable.

---

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

---

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The unaudited preliminary information is attached hereafter. The Company currently expects to lodge audited financial statements for the year ended 30 June 2026 by 30 September 2026.

---

11. Attachments

Details of attachments (if any):

The unaudited Appendix 4E - Preliminary Final Report of AnteoTech Ltd for the year ended 30 June 2026 is attached.

---

12. Signed

Signed ____________________________ Date: 31 August 2026

Ms Merrill Gray
Managing Director and Chief Executive Officer
Eight Mile Plains

Directors	Ms Glenda McLoughlin, Chair Dr Geoffrey Cumming Ms Merrill Gray
Company secretary	Mr Scott Waddell
Registered office and principal place business	4/26 Brandl Street Eight Mile Plains QLD 4113
Share register	MUFG Corporate Markets Level 21, 10 Eagle Street Brisbane, QLD 4000
Auditor	BDO Audit Pty Ltd Level 18, 360 Queen Street Brisbane, QLD 4000
Legal advisors	Sparke Helmore Lawyers Level 23, 240 Queen Street Brisbane QLD 4000
Bankers	Australia and New Zealand Banking Group Limited 1/3215 Logan Road, Underwood QLD 4119
Stock exchange listing	AnteoTech Ltd shares are listed on the Australian Securities Exchange (ASX code: ADO)
Website	www.anteotech.com
Corporate Governance Statement	The Directors and management are committed to conducting the business of AnteoTech Ltd in an ethical manner and in accordance with the highest standards of corporate governance. AnteoTech Ltd has adopted and substantially complied with the ASX Corporate Governance Principles and Recommendations (Fourth Edition) ('Recommendations') to the extent appropriate to the size and nature of its operations. The Corporate Governance Statement and Policy, which sets out the corporate governance practices that were in operation during the financial year and identifies and explains any Recommendations that have not been followed, was approved by the Board of Directors at the same time as the Annual Report and can be found on the AnteoTech website at https://www.anteotech.com/corporate-governance-company-policy/

AnteoTech Ltd and its controlled entities
Consolidated statement of profit or loss and other comprehensive income
For the year ended 30 June 2026

	Note	Consolidated 2026 $	Consolidated 2025 $
Revenue from contracts with customers	5	467,589	968,878
Other income	6	2,598,354	2,431,020
Interest revenue		63,201	58,830
Total revenue and other income		3,129,144	3,458,728
Expenses			
Administration expenses	7	(2,555,444)	(3,849,634)
Depreciation and amortisation expense	7	(1,124,807)	(1,123,382)
Selling and distribution expenses		(696,606)	(640,497)
Share-based payments expenses	19	(522,104)	(643,367)
Occupancy expenses		(134,873)	(81,259)
Research expenses	7	(3,023,384)	(3,879,724)
Total expenses		(8,057,218)	(10,217,863)
Loss before income tax expense		(4,928,074)	(6,759,135)
Income tax expense		-	-
Loss after income tax expense for the year attributable to the owners of AnteoTech Ltd		(4,928,074)	(6,759,135)
Other comprehensive income for the year, net of tax		-	-
Total comprehensive income for the year attributable to the owners of AnteoTech Ltd		(4,928,074)	(6,759,135)
		Cents	**Cents**
Basic earnings per share	18	(0.17)	(0.26)
Diluted earnings per share	18	(0.17)	(0.26)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

AnteoTech Ltd and its controlled entities
Consolidated statement of financial position
As at 30 June 2026

	Note	Consolidated 2026 $	Consolidated 2025 $
Assets			
Current assets			
Cash and cash equivalents	8	5,700,745	2,340,306
Trade and other receivables		134,690	90,859
Other	9	5,710,034	295,797
Total current assets		11,545,469	2,726,962
Non-current assets			
Property, plant and equipment	10	1,020,855	1,398,870
Right-of-use assets	11	2,475,851	1,964,584
Other	9	356,471	356,471
Total non-current assets		3,853,177	3,719,925
Total assets		15,398,646	6,446,887
Liabilities			
Current liabilities			
Trade and other payables	12	505,120	438,853
Borrowings		5,209	4,768
Lease liabilities	13	558,353	545,569
Provisions	14	358,167	319,186
Total current liabilities		1,426,849	1,308,376
Non-current liabilities			
Borrowings		9,250	14,459
Lease liabilities	13	1,574,609	1,394,770
Provisions	14	589,400	579,077
Total non-current liabilities		2,173,259	1,988,306
Total liabilities		3,600,108	3,296,682
Net assets		11,798,538	3,150,205
Equity			
Contributed equity	15	116,831,193	103,776,890
Reserve	16	6,551,149	6,029,045
Accumulated losses		(111,583,804)	(106,655,730)
Total equity		11,798,538	3,150,205

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

AnteoTech Ltd and its controlled entities
Consolidated statement of changes in equity
For the year ended 30 June 2026

Consolidated	Issued capital $	Reserve $	Accumulated losses $	Total equity $
Balance at 1 July 2024	99,816,840	5,385,678	(99,896,595)	5,305,923
Loss after income tax expense for the year	-	-	(6,759,135)	(6,759,135)
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive income for the year	-	-	(6,759,135)	(6,759,135)
Transactions with owners in their capacity as owners:				
Contributions of equity, net of transaction costs (note 15)	3,960,050	-	-	3,960,050
Options expensed for the period (note 16)	-	965,673	-	965,673
Options forfeited during the period (note 16)	-	(322,306)	-	(322,306)
Balance at 30 June 2025	103,776,890	6,029,045	(106,655,730)	3,150,205

Consolidated	Issued capital $	Reserve $	Accumulated losses $	Total equity $
Balance at 1 July 2025	103,776,890	6,029,045	(106,655,730)	3,150,205
Loss after income tax expense for the year	-	-	(4,928,074)	(4,928,074)
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive income for the year	-	-	(4,928,074)	(4,928,074)
Transactions with owners in their capacity as owners:				
Contributions of equity, net of transaction costs (note 15)	13,054,303	-	-	13,054,303
Options expensed for the period (note 16)	-	544,059	-	544,059
Options forfeited during the period (note 16)	-	(21,955)	-	(21,955)
Balance at 30 June 2026	116,831,193	6,551,149	(111,583,804)	11,798,538

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

AnteoTech Ltd and its controlled entities
Consolidated statement of cash flows
For the year ended 30 June 2026

	Note	Consolidated 2026 $	Consolidated 2025 $
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		410,019	1,122,555
Payments to suppliers and employees (inclusive of GST)		(6,512,996)	(9,328,973)
		(6,102,977)	(8,206,418)
Interest received		63,201	58,830
Other income		2,598,354	2,385,553
Interest and other finance costs paid		(88,215)	(64,154)
Net cash used in operating activities		(3,529,637)	(5,826,189)
Cash flows from investing activities			
Payments for term deposit		(5,500,000)	-
Payments for property, plant and equipment	10	(54,934)	(220,337)
Proceeds from disposal of property, plant and equipment		-	45,467
Net cash used in investing activities		(5,554,934)	(174,870)
Cash flows from financing activities			
Proceeds from issue of shares	15	3,808,350	4,310,606
Principal repayment of leases		(604,525)	(639,436)
Proceeds from exercise of options	15	10,032,004	35
Share issued transaction costs	15	(786,051)	(350,591)
Repayment of borrowings		(4,768)	(4,365)
Net cash from financing activities		12,445,010	3,316,249
Net increase/(decrease) in cash and cash equivalents		3,360,439	(2,684,810)
Cash and cash equivalents at the beginning of the financial year		2,340,306	5,025,116
Cash and cash equivalents at the end of the financial year	8	5,700,745	2,340,306

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

Note 1. General information

The financial statements cover AnteoTech Ltd as a Group consisting of AnteoTech Ltd (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled (collectively referred to hereafter as the 'Group' or 'AnteoTech') at the end of, or during, the year. The financial statements are presented in Australian dollars, which is AnteoTech Ltd's functional and presentation currency.

AnteoTech Ltd is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

4/26 Brandl Street,
Eight Mile Plains QLD 4113

Rounding of amounts
The Company is of a kind referred to in Corporations Instrument 2026/183, issued by the Australian Securities and Investments Commission, relating to 'rounding off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest dollar.

Note 2. Material accounting policy information

The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.

Statement of compliance
This preliminary final report (the Report) is to be read in conjunction with any public announcements made by AnteoTech Ltd during the reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001 and Australian Securities Exchange Listing Rules.

The preliminary final report has been prepared in accordance with Australian Accounting Standards (AASBs) adopted by the Australian Accounting Standards Board and the Corporations Act 2001.

Going concern
The consolidated financial statements have been prepared on a going concern basis which contemplates the continuity of normal business activities and the realisation of assets and discharge of liabilities in the ordinary course of business.

As at 30 June 2026, the Group has net assets of $11,798,538 (2025: $3,150,205) ;cash and cash equivalents of $5,700,745 (2025: $2,340,306) plus current term deposits of $5,500,000 (2025: $nil), and debt in the form of asset financing of $14,459 (2025: $19,227).

The Company received additional funding in January and February 2026 through a $3,808,350 Share Placement (before costs). The shares issued under the Placement were priced at 1.55 cents per share with two attaching options per two shares acquired (one option was listed and the other option was unlisted. The listed options have expired as at 30 June 2026). The exercise of all the Company's 286,628,688 listed ADOO options at A$0.035, raised $10,032,004 (before costs) and materially strengthened the Company balance sheet.

As the Group is currently loss making, the Group's ability to continue to adopt the going concern assumption will depend upon a number of matters including the successful sales and/or commercialisation of the Group's intellectual property and projects as well as successful capital injection in the future.

The Directors acknowledge that whilst a requirement may exist for the Company to raise funds in the future, there will continue to be a material uncertainty that may cast significant doubt regarding the Group's ability to continue as a going concern and therefore, the Group may be unable to realise their assets and discharge their liabilities in the normal course of business.

The Directors believe that the Group will be able to continue as a going concern, which contemplates continuity of normal business activities and the realisation of assets and the settlement of liabilities in the ordinary course of business and as a result the financial statements have been prepared on a going concern basis.

Nevertheless, after taking into account the current financial position of the Group, the Group's ability to raise further capital, the ability to control costs and the progress made on the commercialisation of its intellectual

Note 2. Material accounting policy information (continued)

property, the Directors have a reasonable expectation that the Group will have adequate resources to fund its future operational requirements and for these reasons they continue to adopt the going concern basis in preparing the financial report.

Key activities supporting the Group's ability to continue as a concern include:

- Several Advanced Battery Technologies commercial opportunities progressing through negotiation and product validation, including through:
    - a joint development terms agreement with Black Diamond Structures for a combined product using Anteo X™ (SiMRAX);
    - the sales and collaboration agreement with Xerabrid in relation to high-performance ceramic coated separators using Anteo S;
    - the evaluation of Ultranode™ for potential commercial scale use by Wyon AG; and
    - negotiations in relation to Joint Development Agreements with other battery manufacturers in relation to Ultranode™ 95.
- Business Development and potential sales growth from Life Sciences customers has focused on the high growth Indian market, Japan, South Korea, and increasingly the USA, and has identified a number of further opportunities where ongoing engagement is progressing positively with a number of prospective customers in relation to sales.
- Market entry opportunities into new jurisdictions and applications for AnteoTech are being executed as per the Strategic Review outcomes, prioritising sales of the Company's market ready products and technologies and investing in the sales and marketing capability to successfully and expediently convert sales and grow revenues.
- A reduced cost base through Company restructuring with further cost initiatives has been implemented, with continuous improvement underway.
- The Group continues to explore opportunities to fund and co-fund development of customised solutions and grow with potential strategic partners.

In the unlikely scenario where the Group is unable to continue as a going concern, it may be required to realise its assets and extinguish its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the consolidated financial statements.

Note 3. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Share-based payment transactions
The Group measures the cost of equity-settled share-based payment transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Monte Carlo or Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Note 3. Critical accounting judgements, estimates and assumptions (continued)

Lease term
The lease term is a significant component in the measurement of both the right-of-use asset and lease liability. Judgement is exercised in determining whether there is reasonable certainty that an option to extend the lease or purchase the underlying asset will be exercised, or an option to terminate the lease will not be exercised, when ascertaining the periods to be included in the lease term. In determining the lease term, all facts and circumstances that create an economical incentive to exercise an extension option, or not to exercise a termination option, are considered at the lease commencement date. Factors considered may include the importance of the asset to the Group's operations; comparison of terms and conditions to prevailing market rates; incurrence of significant penalties; existence of significant leasehold improvements; and the costs and disruption to replace the asset. The Group reassesses whether it is reasonably certain to exercise an extension option, or not exercise a termination option, if there is a significant event or significant change in circumstances.

Incremental borrowing rate
Where the interest rate implicit in a lease cannot be readily determined, an incremental borrowing rate is estimated to discount future lease payments to measure the present value of the lease liability at the lease commencement date. Such a rate is based on what the Group estimates it would have to pay a third party to borrow the funds necessary to obtain an asset of a similar value to the right-of-use asset, with similar terms, security and economic environment.

Lease make good provision
A provision has been made for the present value of anticipated costs for future restoration of leased premises. The provision includes future cost estimates associated with closure of the premises. The calculation of this provision requires assumptions such as application of closure dates and cost estimates. The provision recognised for each site is periodically reviewed and updated based on the facts and circumstances available at the time. Changes to the estimated future costs for sites are recognised in the statement of financial position by adjusting the asset and the provision. Reductions in the provision that exceed the carrying amount of the asset will be recognised in profit or loss.

Note 4. Operating segments

Identification of reportable operating segments
The Group has determined that it has only one operating segment. The operating segment identified is based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources.

While the Group's activities span the sales and marketing of its core chemical platform technology in two markets(Advanced Battery Technologies and Life Sciences) these applications and share common costs, including support personnel, premises, research infrastructure and corporate functions. Discrete financial information is not prepared or reviewed at a business for the purposes of assessing corporate performance or allocating resources. References to these businesses in the Directors' Report, Operating and Financial Review and market announcements reflect the nature of the Group's activities and are not indicative of separate financial reporting to the CODM.

Management currently identifies the Group as having only one operating segment, being the development and commercialisation of AnteoTech's intellectual property and advanced chemicals and materials technologies. All significant operating decisions are based upon analysis of the Group as one segment. The financial results from the segment are equivalent to the consolidated financial statements of the Group as a whole.

Major customers
During the year ended 2026 approximately 59.0% (2025: 81.0%) of the Group's external revenue was derived from sales to one customer.

Accounting policy for operating segments
Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

Note 5. Revenue from contracts with customers

	Consolidated 2026 $	Consolidated 2025 $
Product sales	402,994	885,415
Licence fees and royalties	-	30,963
Contract services	64,595	52,500
Revenue from contracts with customers	467,589	968,878

Note 6. Other income

	Consolidated 2026 $	Consolidated 2025 $
Profit on disposal of property, plant and equipment	-	45,467
R&D tax concession	2,588,632	2,385,553
Other	9,722	-
Other income	2,598,354	2,431,020

Note 7. Expenses

	Consolidated 2026 $	Consolidated 2025 $
Loss before income tax includes the following specific expenses:		
Depreciation		
Plant and equipment	210,801	212,353
Fixtures, fittings and office equipment	221,675	224,059
Land and buildings right-of-use assets	692,331	686,970
Total depreciation	1,124,807	1,123,382
Employee benefits expenses - total		
Salaries and fees	2,950,918	4,314,497
Superannuation contributions	320,554	409,170
Share-based payments	522,104	643,367
	3,793,576	5,367,034
Administrative expenses		
Staff related expenses	1,402,184	1,941,836
Directors' fees	207,795	335,000
Professional services	336,906	671,523
Other administrative costs	608,559	901,275
	2,555,444	3,849,634
Research expenses		
Staff related expenses	2,233,191	2,818,564
Lab and material equipment	417,764	624,487
Consulting	372,429	436,673
	3,023,384	3,879,724
Finance costs		
Interest and finance charges paid/payable on lease liabilities	88,215	64,154
Leases		
Short-term lease payments	2,388	1,722

Note 8. Cash and cash equivalents

	Consolidated 2026 $	Consolidated 2025 $
Current assets		
Cash on hand	2,564	2,691
Cash at bank*	5,698,181	2,337,615
	5,700,745	2,340,306

* Excluding the $5,500,000 6-month Term Deposit maturing on 18 December 2026 and detailed in note 9.

Note 9. Other

	Consolidated 2026 $	Consolidated 2025 $
Current assets		
Prepayments	210,034	295,797
Term deposit	5,500,000	-
	5,710,034	295,797
Non-current assets		
Term deposit	30,000	30,000
Bank guarantees	326,471	326,471
	356,471	356,471
	6,066,505	652,268

Term deposit
Term deposits with original maturities exceeding three months are classified as other financial assets. As at 30 June 2026, this includes a $5,500,000 6-month term deposit maturing on 18 December 2026.

Note 10. Property, plant and equipment

	Consolidated 2026 $	Consolidated 2025 $
Non-current assets		
Plant and equipment - at cost	2,424,266	2,522,280
Less: Accumulated depreciation	(1,935,493)	(1,847,108)
	488,773	675,172
Fixtures, fittings and office equipment - at cost	1,362,389	1,682,977
Less: Accumulated depreciation	(830,307)	(959,279)
	532,082	723,698
	1,020,855	1,398,870

Note 10. Property, plant and equipment (continued)

Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated	Plant and equipment $	Fixtures, fittings and office equipment $	Total $
Balance at 1 July 2024	675,817	939,142	1,614,959
Additions	211,708	8,878	220,586
Disposals	-	(263)	(263)
Depreciation expense	(212,353)	(224,059)	(436,412)
Balance at 30 June 2025	675,172	723,698	1,398,870
Additions	24,402	30,532	54,934
Disposals	-	(473)	(473)
Depreciation expense	(210,801)	(221,675)	(432,476)
Balance at 30 June 2026	488,773	532,082	1,020,855

Comparatives
Comparative information has been restated to reclassify assets with a net book value of $3,761 from property, plant and equipment to right-of-use assets to correct the prior year presentation.

Note 11. Right-of-use assets

	Consolidated 2026 $	Consolidated 2025 $
Non-current assets		
Land and buildings - right-of-use	3,805,314	4,346,949
Less: Accumulated depreciation	(1,329,463)	(2,382,365)
	2,475,851	1,964,584

The Group leases office space. Rental contracts are typically made for fixed periods of 1 to 5 years but may have extension options. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor.

The Group leases office equipment under agreements of various terms. Leases that are low-value or less than 12 months are expensed as incurred and not capitalised as right-of-use assets

Comparatives
Comparative information has been restated to reclassify assets with a net book value of $3,761 from property, plant and equipment to right-of-use assets to correct the prior year presentation.

Note 11. Right-of-use assets (continued)

Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated	Land and buildings $
Balance at 1 July 2024	2,282,395
Lease make good provision	100,000
Lease adjustments/modifications	269,159
Depreciation expense	(686,970)
Balance at 30 June 2025	1,964,584
Lease make good provision	406,450
Lease modification	797,148
Depreciation expense	(692,331)
Balance at 30 June 2026	2,475,851

The lease modification is a result of the extension of the lease for 26 Brandl Street through to 30 November 2029.

Note 12. Trade and other payables

	Consolidated 2026 $	2025 $
Current liabilities		
Trade payables	254,715	262,375
Sundry creditors and accrued expenses	250,405	176,478
	505,120	438,853

The amounts are unsecured and are usually paid within 14 to 30 days of recognition.

Note 13. Lease liabilities

	Consolidated 2026 $	2025 $
Current liabilities		
Lease liability	558,353	545,569
Non-current liabilities		
Lease liability	1,574,609	1,394,770
	2,132,962	1,940,339

Note 14. Provisions

	Consolidated 2026 $	Consolidated 2025 $
Current liabilities		
Annual leave	231,820	202,944
Long service leave	126,347	116,242
	358,167	319,186
Non-current liabilities		
Long service leave	61,357	31,497
Lease make good	528,043	547,580
	589,400	579,077
	947,567	898,263

Lease make good
The provision represents the present value of the estimated costs to make good the premises leased by the Group at the end of the respective lease terms.

Movements in lease make good provision
Movements in the lease make good provision during the current financial year are set out below:

	Consolidated 2026 $	Consolidated 2025 $
Carrying amount at the start of the year	547,580	551,833
Recognition of make good provision	406,450	100,000
Derecognition of make good provision through profit or loss	(447,580)	-
Fair value remeasurement	-	(178,000)
Interest	21,593	73,747
	528,043	547,580

Note 15. Contributed equity

	Consolidated 2026 Shares	2025 Shares	2026 $	2025 $
Ordinary shares - fully paid	3,259,767,301	2,705,300,325	116,831,193	103,776,890

Note 15. Contributed equity (continued)

Movements in ordinary share capital

Details	Date	Shares	Issue price	$
Balance	1 July 2024	2,468,287,352		99,816,840
Shares issued - exercise of options	31 July 2024	352,200	$0.0001	35
Shares issued - employee incentives	13 September 2024	21,130,463	$0.0000	-
Shares issued - placement	20 November 2024	175,000,000	$0.0200	3,500,000
Shares issued - entitlement offer	16 December 2024	40,530,310	$0.0200	810,606
Share issue costs				(350,591)
Balance	30 June 2025	2,705,300,325		103,776,890
Shares issued - employee incentives	28 August 2025	22,138,295	$0.0000	-
Shares issued - placement	5 February 2026	245,699,993	$0.0155	3,808,350
Shares issued - exercise of options	2 June 2026	118,326,435	$0.0350	4,141,425
Shares issued - exercise of options	5 June 2026	168,302,253	$0.0350	5,890,579
Share issue costs				(786,051)
Balance	30 June 2026	3,259,767,301		116,831,193

Note 16. Reserve

	Consolidated 2026 $	Consolidated 2025 $
Share-based payments reserve	6,551,149	6,029,045

Refer to note 19 for further details.

Share-based payments reserve
The reserve is used to recognise the value of equity benefits provided to employees and Directors as part of their remuneration, and other parties as part of their compensation for services.

Movements in reserves
Movements in each class of reserve during the current and previous financial year are set out below:

Consolidated	Share-based payments reserve $
Balance at 1 July 2024	5,385,678
Options expense	965,673
Options lapsed	(322,306)
Balance at 30 June 2025	6,029,045
Options expense	544,059
Options lapsed	(21,955)
Balance at 30 June 2026	6,551,149

Note 17. Contingent liabilities

The Group has provided bank guarantees totalling $326,471 in favour of the lessor as security for its obligations under its lease agreements. No amounts have been recognised as liabilities in relation to these guarantees, as no claims have been made against them at the reporting date.

Note 18. Earnings per share

	Consolidated 2026 $	Consolidated 2025 $
Loss after income tax attributable to the owners of AnteoTech Ltd	(4,928,074)	(6,759,135)
	Number	**Number**
Weighted average number of ordinary shares used in calculating basic earnings per share	2,842,071,596	2,613,600,684
Weighted average number of ordinary shares used in calculating diluted earnings per share	2,842,071,596	2,613,600,684
	Cents	**Cents**
Basic earnings per share	(0.17)	(0.26)
Diluted earnings per share	(0.17)	(0.26)

Options are considered to be potential ordinary shares. For the years ended 30 June 2026 and 30 June 2025 their conversion to ordinary shares would have had the effect of reducing the loss per share and therefore considered to be anti-dilutive. Accordingly, the options were not included in the determination of diluted earnings per share. There were 297,958,151 unlisted options on issue as at 30 June 2026 which have not been considered for loss per share calculations (2025: 148,422,458 listed and 153,888,483 unlisted options).

The unlisted options not associated with share-based options outstanding at the end of 2026 and their movement during the year were as follows:

2026

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Forfeited	Expired	Balance at the end of the year
13/09/2023	13/09/2026	$0.0640	71,376,921	-	-	-	71,376,921
14/11/2023	13/09/2026	$0.0640	1,875,000	-	-	-	1,875,000
01/09/2023	30/11/2026	$0.0640	5,000,000	-	-	-	5,000,000
04/02/2026	31/01/2028	$0.0350	-	138,206,230	-	-	138,206,230
			78,251,921	138,206,230	-	-	216,458,151

The 71,376,921 and 138,206,230 options relate to the attaching options issued as part of the issue of ordinary shares under the placement and share purchase plan during the current and previous periods. For the options granted on 4 February 2026, one attaching unlisted option was issued for every two ordinary shares acquired. One attaching listed option was also issued for every two ordinary shares acquired; however, this section is for unlisted options only. These do not form part of any remuneration and thereby not subject to AASB 2 Share based payments.

The unlisted options outstanding at the end of 2025 and their movement during the year were as follows:

Note 18. Earnings per share (continued)

2025

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Forfeited	Expired	Balance at the end of the year
13/09/2023	13/09/2026	$0.0640	71,376,921	-	-	-	71,376,921
14/11/2023	13/09/2026	$0.0640	1,875,000	-	-	-	1,875,000
01/09/2023	30/11/2026	$0.0640	5,000,000	-	-	-	5,000,000
			78,251,921	-	-	-	78,251,921

The 71,376,921 options relate to the attaching options issued as part of the issue of ordinary shares under the placement and share purchase plan during the previous period. One attaching option was issued for every two ordinary shares acquired. These do not form part of any remuneration and thereby not subject to AASB 2 Share based payments.

Note 19. Share-based payments

The Group has an Employee Share Option Scheme for Directors, senior executives, employees and key consultants of the Group whereby those parties may be granted options to purchase ordinary shares in the Company. There were 30,500,000 (2025: 20,100,000) options issued under the Equity Incentive Plan during the year (excluding 42,500,000 Director options granted post the Annual General Meeting). 118,326,435 shares were issued on 2 June 2026 from option exercises; and 168,302,253 shares were issued on 5 June 2026 from option exercises; and other than these two tranches, no other options were exercised during the year (2025: 352,200) (issued in prior periods) with 24,425,625 (2025: 61,488,253) options lapsing.

Set out below are summaries of options granted under the plan:

The unlisted options outstanding at the end of 2026 and their movement during the year were as follows:

2026

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Forfeited	Expired	Balance at the end of the year
11/10/2022	31/07/2025	$0.0001	1,254,687	-	(1,050,625)	(204,062)	-
17/11/2022	04/10/2026	$0.1125	20,000,000	-	-	(20,000,000)	-
16/12/2022	31/07/2025	$0.0001	431,875	-	-	(431,875)	-
14/11/2023	30/11/2026	$0.0480	33,750,000	-	(3,750,000)	(19,500,000)	10,500,000
15/10/2024	26/11/2027	$0.0480	17,700,000	-	(10,725,000)	(2,575,000)	4,400,000
01/01/2025	26/11/2027	$0.0480	2,500,000	-	-	-	2,500,000
19/08/2025	19/08/2029	$0.0375	-	30,000,000	-	-	30,000,000
24/10/2025	19/08/2029	$0.0375	-	24,800,000	(8,900,000)	-	15,900,000
26/11/2025	26/11/2028	$0.0375	-	12,500,000	-	-	12,500,000
24/06/2026	19/08/2029	$0.0375	-	5,700,000	-	-	5,700,000
			75,636,562	73,000,000	(24,425,625)	(42,710,937)	81,500,000

The unlisted options outstanding at the end of 2025 and their movement during the year were as follows:

Note 19. Share-based payments (continued)

2025

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
02/08/2021	30/06/2025	$0.0001	352,200	-	(352,200)	-	-
02/08/2021	31/07/2025	$0.0001	235,600	-	-	(235,600)	-
01/12/2021	31/07/2025	$0.0001	-	-	-	-	-
11/10/2022	31/07/2025	$0.0001	2,007,500	-	-	(752,813)	1,254,687
11/10/2022	31/12/2025	$0.0001	3,041,160	-	-	(3,041,160)	-
17/11/2022	21/04/2025	$0.1603	7,000,000	-	-	(7,000,000)	-
17/11/2022	21/04/2025	$0.1603	13,500,000	-	-	(13,500,000)	-
17/11/2022	04/10/2026	$0.1125	30,000,000	-	-	(10,000,000)	20,000,000
16/12/2022	31/12/2025	$0.0001	38,355	-	-	(38,355)	-
16/12/2022	31/07/2025	$0.0001	2,902,200	-	-	(2,470,325)	431,875
14/11/2023	30/11/2026	$0.0480	44,500,000	-	-	(10,750,000)	33,750,000
15/10/2024	26/11/2027	$0.0480	-	20,600,000	-	(2,900,000)	17,700,000
26/11/2024	26/11/2027	$0.0480	-	10,800,000	-	(10,800,000)	-
01/01/2025	26/11/2027	$0.0480	-	2,500,000	-	-	2,500,000
			103,577,015	33,900,000	(352,200)	(61,488,253)	75,636,562
Weighted average exercise price					$0.0001		

The 10,800,000 options issued relate to those options approved at the annual general meeting in November 2024 to be issued to the previous the Managing Director and Chief Executive Officer. The options have lapsed due to the resignation of the previous Managing Director and Chief Executive Officer prior to vesting.

The number of options vested and exercisable at the end of each reporting period were as follows:

	Consolidated 2026 Number	Consolidated 2025 Number
Options vested and exercisable	230,408,151	106,813,483
Options not yet vested	67,550,000	47,075,000
Total options outstanding	297,958,151	153,888,483

Options not yet vested at 30 June 2026 are subject to the following vesting conditions:

The option tranche granted 15 October 2024 has 2,200,000 options which vest on 26 November 2026. The options will be forfeited if the holder ceases employment prior to the vesting date, unless the Board determines otherwise.

The option tranche granted 1 January 2025 has 1,250,000 options which vest on 26 November 2026. The options will be forfeited if the holder ceases employment prior to the vesting date, unless the Board determines otherwise.

The option tranche granted 19 August 2025 has 30,000,000 options which vest based on the conditions outlined in the section below titled “Valuation model - 2026 unlisted MD/CEO options”

The option tranche granted 24 October 2025 has 15,900,000 options which vest based on the conditions outlined in the section below titled “Valuation model - 2026 unlisted senior staff options”.

The option tranche granted 26 November 2025 has 12,500,000 options which vest based on the conditions outlined in the section below titled “Valuation model - 2026 unlisted Non-Executive Director Options”.

Note 19. Share-based payments (continued)

The option tranche granted 26 June 2026 has 5,700,000 options which vest based on the conditions outlined in the section below titled "Valuation model - 2026 unlisted senior staff options".

The number of unlisted options issued to Directors, staff or third parties in relation to services rendered during the current and previous year are summarised below:

	Consolidated 2026 Number	Consolidated 2025 Number
Directors Options	12,500,000	-
CEO Options	30,000,000	10,800,000
Staff Options	30,500,000	20,100,000
Third-Party Options	-	3,000,000
	73,000,000	33,900,000

The number of performance rights issued to Directors, staff or third parties in relation to services rendered during the current and previous year are summarised below:

	Consolidated 2026 Number	Consolidated 2025 Number
Balance at the start of the year	-	2,820,000
Converted to ordinary shares	-	(2,820,000)
Granted	-	5,400,000
Lapsed	-	(5,400,000)
Balance at end of the year	-	-

The fair value of the options granted during the year ended 30 June 2026 were all determined by the Company using a Monte Carlo pricing model that takes into account the share price at grant date, exercise price, expected volatility of 90% (determined by reference to historical volatility of the share price of similar companies), price hurdles, option life and risk-free rate.

Valuation model - 2026 unlisted Non-Executive Director Options (approved at the annual general meeting)

Grant date	Expiry date	Number issued	Share price at grant date $	Exercise price $	Risk-free rate %	Hurdle price $	Fair value at grant date per option $
26/11/2025	26/11/2028	6,250,000	$0.0190	$0.0375	3.75%	$0.0375	$0.0082
26/11/2025	26/11/2028	6,250,000	$0.0190	$0.0375	3.75%	$0.0500	$0.0081
		12,500,000					

Note 19. Share-based payments (continued)

The options will vest as follows:

No. of options	Vesting condition Share Price Hurdle (being the 60-trading day VWAP of Shares – to be achieved on or before the date the options expire)	Vesting condition Service Period Condition (during which the Directors must remain continuously employed by the Company)
6,250,000	$0.0375	12 months from commencement date
6,250,000	$0.0500	24 months from commencement date

Valuation model - 2026 unlisted MD/CEO options (approved at the annual general meeting)

Grant date	Expiry date	Number issued	Share price at grant date $	Exercise price $	Risk-free rate %	Hurdle price[1] $	Fair value at grant date per option $
26/11/2025	19/08/2029	10,000,000	$0.0190	$0.0375	3.75%	$0.0375	$0.0090
26/11/2025	19/08/2029	10,000,000	$0.0190	$0.0375	3.75%	$0.0500	$0.0087
26/11/2025	19/08/2029	10,000,000	$0.0190	$0.0375	3.75%	$0.0625	$0.0088
		30,000,000					

[1] Being the 60-trading average of shares – to be achieved on or before expiry date.

The options issued to the CEO were approved by shareholders at the AGM on 26 November 2025. The options are subject to service conditions and will be dependent on the employee remaining in employment as at vesting date. The fair value was re-estimated on the AGM date (26/11/2025) after initially measuring at service commencement date of 19/8/2025.

The options will vest as follows:

No. of options	Vesting condition Share Price Hurdle (being the 60-trading day VWAP of Shares – to be achieved on or before the date the options expire)	Vesting condition Service Period Condition (during which the MD & CEO must remain continuously employed by the Company)
10,000,000	$0.0375	12 months from commencement date
10,000,000	$0.0500	24 months from commencement date
10,000,000	$0.0625	36 months from commencement date

Valuation model - 2026 unlisted senior staff options

Grant date	Expiry date	Number issued	Share price at grant date $	Exercise price $	Risk-free rate %	Hurdle price[1] $	Fair value at grant date per option $
14/10/2025	19/08/2029	12,400,000	$0.0220	$0.0375	3.75%	$0.0375	$0.0090
14/10/2025	19/08/2029	12,400,000	$0.0220	$0.0375	3.75%	$0.0500	$0.0087
24/06/2026	19/08/2029	2,850,000	$0.0280	$0.0375	4.35%	$0.0375	$0.0179
24/06/2026	19/08/2029	2,850,000	$0.0280	$0.0375	4.35%	$0.0500	$0.0178
		30,500,000					

[1] Being the 60-trading average of shares – to be achieved on or before expiry date.

Note 19. Share-based payments (continued)

The 24,800,000 options issued to senior staff were approved by the Board on 14 October 2025. The options are subject to service conditions and will be dependent on the employees remaining in employment as at the vesting date.

The fair value of the options were determined by the Company using a Monte Carlo pricing model that takes into account the share price at grant date, exercise price, expected volatility of 90% (determined by reference to historical volatility of the share price of similar companies), price hurdles, option life and risk-free rate.

The 5,700,000 options issued to senior staff with a Grant Date of 24 June 2026. The options are subject to both service and share price performance conditions and will vest only if the applicable vesting conditions are satisfied, including the employee remaining in employment at the vesting date.

The fair value of the options were determined by the Company using a Monte Carlo pricing model that takes into account the share price at grant date, exercise price, expected volatility of 111% (determined by reference to historical volatility of the share price of AnteoTech shares), price hurdles, option life and risk-free rate.

No. of options	**Vesting condition** **Share Price Hurdle** (being the 60-trading day VWAP of Shares – to be achieved on or before the date the options expire)	**Vesting condition** **Service Period Condition** (during which the employee must remain continuously employed by the Company)
12,400,000	$0.0375	12 months from commencement date
12,400,000	$0.0500	24 months from commencement date
2,850,000	$0.0375	12 months from commencement date
2,850,000	$0.0500	24 months from commencement date

	Consolidated **2026** **$**	 **2025** **$**
Allocation of value of options issued to staff during 2022	-	554
Allocation of value of options issued to CEO during 2023[1]	-	88,488
Allocation of value of options issued to staff during 2023	95	3,340
Allocation of value of options issued to CEO during 2024[2]	-	47,231
Allocation of value of options issued to Directors during 2024[3]	4,484	38,350
Allocation of value of performance rights issued to CEO during 2024[4]	-	16,222
Allocation of value of options issued to staff during 2024[5]	25,058	206,112
Allocation of value of options issued to third parties during 2024[6]	-	10,616
Allocation of value of options issued to CEO during 2025[7]	-	18,723
Allocation of value of performance rights issued to CEO during 2025[8]	-	21,830
Allocation of value of options issued to staff during 2025[9]	26,657	193,018
Allocation of value of options issued to third parties during 2025[10]	-	5,200
	45,308	
Allocation of value of options issued to Directors during 2026[11]		-
Allocation of value of options issued to CEO during 2026[12]	140,504	-
Allocation of value of options issued to staff during 2026[13]	78,695	-
	223,257	
Allocation of value of equity settled incentives to be issued to staff[14]		315,989
Adjustment for forfeited options	(21,955)	(322,306)
Total share-based payments expenses	522,104	643,367

Note 19. Share-based payments (continued)

[1] Options issued to the CEO during 2023 were approved by shareholders at the AGM on 17 November 2022, being the grant date.
[2] 10,000,000 long-term incentive options were granted to the CEO and approved at the AGM on the 14 November 2023.
[3] 7,000,000 long-term incentive options were granted to Directors and approved at the AGM on the 14 November 2023.
[4] Up to 2,820,000 performance awards were granted to the CEO and approved at the AGM on the 14 November 2023 as part of a short-term incentive award.
[5] 27,500,000 long-term incentive options were granted to senior staff under the Company's Equity Incentive Plan.
[6] 5,000,000 long-term options were issued to third parties in relation to ongoing advisory services.
[7] 10,800,000 long-term incentive options were granted to the CEO and approved at the AGM on the 26 November 2024.
[8] Up to 5,400,000 performance awards were granted to the CEO and approved at the AGM on the 26 November 2024 as part of a short-term incentive award.
[9] 17,600,000 long-term incentive options were granted to senior staff under the Company's Equity Incentive Plan.
[10] 3,000,000 long-term options were issued to third parties in relation to ongoing executive services.
[11] Up to 12,500,000 long-term options were granted to the Directors and approved at the AGM on the 26 November 2025 as part of a long-term incentive award.
[12] Up to 30,000,000 long-term options were granted to the CEO and approved at the AGM on the 26 November 2025 as part of a long-term incentive award.
[13] Up to 30,500,000 long-term options were granted to staff as part of a long-term incentive award.
[14] Employees of the Company are entitled to participate in the Company's short-term incentive (STI) plan. The STI will be settled by the issue of ordinary shares and determined following a review of the non-market performance conditions over the vesting period.

Shareholder Information

The shareholder information set out below was applicable as at 21 August 2026.

Distribution of equitable securities

Analysis of number of equitable security holders by size of holding:

	Ordinary shares	
	Number of holders	% of total shares issued
1 to 1,000	244	2.74
1,001 to 5,000	2,105	23.65
5,001 to 10,000	998	11.21
10,001 to 100,000	3,280	36.85
100,001 and over	2,273	25.54
	8,900	100.00
Holding less than a marketable parcel	4,779	53.70

Equity security holders

Twenty largest quoted equity security holders

The names of the twenty largest security holders of quoted equity securities are listed below:

	Ordinary shares	
	Number held	% of total shares issued
MARCOLONGO NOMINEES PTY LTD	99,024,869	3.04
FIRST CAPE MANAGEMENT PTY LTD	55,195,509	1.69
CITICORP NOMINEES PTY LIMITED	52,095,735	1.60
AWO & CAO INVESTMENTS PTY LTD	48,900,000	1.50
ADDISON LAKE QUALITY HIRE PTY LIMITED	38,844,879	1.19
MR PETER FREDERICK KEMMIS	36,216,676	1.11
BNP PARIBAS NOMINEES PTY LTD	34,418,226	1.06
FOSSIL SUPER PTY LTD	33,920,000	1.04
MR CLAUS KURT DZALAKOWSKI	30,000,000	0.92
BOND STREET CUSTODIANS LIMITED	25,100,000	0.77
BOND STREET CUSTODIANS LIMITED	24,852,749	0.76
MCRAE SUPERANNUATION PTY LTD	24,000,000	0.74
TERRY & LINDEN DEAVIN SUPER PTY LTD	23,500,212	0.72
MR CLAUS KURT DZALAKOWSKI & MRS MICHELLE GAY DZALAKOWSKI	23,000,000	0.71
COMPUTER VISIONS PTY LTD	22,132,994	0.68
MR ANTONIO DI LALLA	21,986,924	0.67
MR GARETH EDWARD GRANT	21,241,009	0.65
MR ROBERT COSIMO MACRI	20,305,134	0.62
MR PHILIP MICHAEL DEAVIN & MRS CHIMENE MAREE DEAVIN	19,162,769	0.59
MR ANTHONY WILLIAM OLDING & MRS CAROLINE ANNE OLDING	18,100,000	0.56
	671,997,685	20.61

Shareholder Information

Unquoted equity securities

Employee Option Plan
The Employee Option Plan last approved by shareholders on 26 November 2024, provides that employees may be issued options to acquire shares in the Company. These options are not quoted on the Australian Stock Exchange.
As at the date of this report, the total number of Options on issue under the Employee Option Plan was 81,500,000.
(a) Other Unlisted Options
The following unlisted options to acquire ordinary shares are on issue as at 21 August 2026:

	Number on issue
Options over ordinary shares issued to directors	5,000,000
Options over ordinary shares issued to other parties	211,458,151
Total unlisted options to acquire ordinary shares	216,458,151

Voting rights
The voting rights attached to ordinary shares are set out below:

Ordinary shares

(a) on a show of hands every member present at a meeting in person or by proxy, attorney or representative will shall have one vote; and
(b) on a poll every member present at a meeting in person or by proxy, attorney or representative will have one vote for each fully paid share held.

There are no other classes of quoted equity securities.